Innovation Summit 2021
Gregory T Tietjen PhD
Founder of Revalia Bio
Our Founding Team & Strategic Partners

Greg Tietjen, PhD  
Lead Founder  
Assistant Professor  
Yale School of Medicine

Shohei Koide, Ph.D.  
Co-Founder  
Professor  
NYU Langone Health

Aaron Ring, PhD  
Co-Founder  
Assistant Professor  
Yale School of Medicine

Expertise:  
- Drug delivery  
- Ex vivo organ repair  
- Clinical Translation

Expertise:  
- Protein Engineering  
- Serial Inventor  
- Multiple Biologics in IND

Expertise:  
- Protein Engineering  
- Serial Entrepreneur  
- Proven Startup Founder

Strategic Partners

CareDx  
Your Partner in Transplant Care
A Disruptive Opportunity to Expand our Donor Organ Pool

We develop therapies specifically tailored to repair injured organs before transplant

Only 0.7% of registered organ donors have their organs recovered upon death

Ex Vivo Organ Perfusion Enables:

- Prolonged preservation & assessment
- Isolated Organ Repair
A Disruptive Opportunity to Expand our Donor Organ Pool

We develop therapies specifically tailored to repair injured organs before transplant

The Cost of Limited Organ Supply

- **Kidney Dialysis Costs**
  - $28.8 billion/yr total

- **Chronic Liver Disease Costs**
  - $18.8 billion/yr total

*Every added transplant yields ~$100k in Medicare savings*
A Disruptive Opportunity to Expand our Donor Organ Pool

We develop therapies specifically tailored to repair injured organs before transplant.

Market Opportunity

- **# of Liver/Kidney Transplants**
  - Current: 25,998/yr
  - Projected: ~40,000/yr

- **Pricing Model**
  - $20,000/treated organ

- **TAM:**
  - Current: $520 million
  - Projected ~$800 million
The Revalia Bio Value Proposition

Rapid Translation via Preclinical Research in Human Organs

Academic Program for Ex Vivo Research In Declined Human Organs

Organ Offer Volume:
• Kidney - ~100-130/yr
• Liver - ~40-50/yr

Our IP Strategy:
Reformulate & Reinvent existing FDA-approved therapies
1) Repair Acute Injury

1\textsuperscript{st}-in-human clinical trial set for Q1 2022

2) Graft-Centered Immunosuppression

Patented Molecular Adaptor

Revalia Bio targeted particles are 1000x more potent than conventional
Revalia Bio Vision and Next Step

- We are poised to earn 1\textsuperscript{st} Mover Status in a Rapid Growth Niche Market
- We’ve established strategic partnerships with world-leaders in transplant
- Current IP position has broad applicability in transplant and beyond

We are seeking additional investment partners to help us realize the full value of our existing (and future) IP